Patents by Inventor Robert W. Tuman
Robert W. Tuman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8557847Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.Type: GrantFiled: April 10, 2009Date of Patent: October 15, 2013Assignee: Janssen Pharmaceutica, N.V.Inventors: Christian Andrew Baumann, Michael David Gaul, Dana L. Johnson, Robert W. Tuman
-
Patent number: 8173654Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: August 7, 2008Date of Patent: May 8, 2012Assignee: Janssen Pharmaceutica N.V.Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
-
Patent number: 8071768Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: June 6, 2006Date of Patent: December 6, 2011Assignee: Janssen Pharmaceutica, N.V.Inventors: Nand Baindur, Michael David Gaul, Kevin Douglas Kreutter, Christian Andrew Baumann, Alexander J. Kim, Guozhang Xu, Robert W. Tuman, Dana L. Johnson
-
Patent number: 8030305Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: December 18, 2006Date of Patent: October 4, 2011Assignee: Janssen Pharmaceutica N.V.Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
-
Patent number: 7816390Abstract: The invention is directed to compounds having the following structures: N-(3-ethoxyphenyl)-1,4-dihydro-6-ethoxy-7-(3-hydroxypropoxy)-1-methylindeno[1,2-c]pyrazole-3-amine; 3-[3-(3-Bromo-phenylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol; or 3-[3-(2-Chloro-pyridin-4-ylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol, and N-oxides, pharmaceutically acceptable salts, solvates, tautomers and stereochemical isomers thereof and the uses of such compounds as inhibitors of tubulin polymerization and for the treatment of solid tumors. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: January 29, 2008Date of Patent: October 19, 2010Assignee: Janssen Pharmaceutica NVInventors: Robert A. Galemmo, Dana L. Johnson, Umar S. M. Maharoof, Jay M. Mei, Robert W. Tuman
-
Patent number: 7795279Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: October 17, 2006Date of Patent: September 14, 2010Assignee: Janssen Pharmaceutica NVInventors: Shelley K. Ballentine, Christian Andrew Baumann, Jinsheng Chen, Carl R. Illig, Sanath K. Meegalla, M. Jonathan Rudolph, Robert W. Tuman, Mark J. Wall, Kenneth Wilson, Dana L. Johnson
-
Patent number: 7795440Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.Type: GrantFiled: January 25, 2007Date of Patent: September 14, 2010Assignee: Janssen Pharmaceutica NVInventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Jr., Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen
-
Patent number: 7662824Abstract: The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: March 16, 2006Date of Patent: February 16, 2010Assignee: Janssen Pharmaceutica NVInventors: Kristi Leonard, Tianbao Lu, Robert W. Tuman, Dana L. Johnson, Anna C. Maroney, Jan L. Sechler, Richard W. Connors, Richard S. Alexander, Maxwell D. Cummings, Robert A. Galemmo, Thomas P. Markotan
-
Publication number: 20090197913Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.Type: ApplicationFiled: April 10, 2009Publication date: August 6, 2009Inventors: Christian Andrew Baumann, Michael David Gaul, Dana L. Johnson, Robert W. Tuman
-
Publication number: 20090098181Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: August 7, 2008Publication date: April 16, 2009Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
-
Publication number: 20080227821Abstract: The invention is directed to compounds having the following structures: N-(3-ethoxyphenyl)-1,4-dihydro-6-ethoxy-7-(3-hydroxypropoxy)-1-methylindeno[1,2-c]pyrazole-3-amine; 3-[3-(3-Bromo-phenylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol; or 3-[3-(2-Chloro-pyridin-4-ylamino)-6-ethoxy-1-methyl-1,4-dihydro-indeno[1,2-c]pyrazol-7-yloxy]-propan-1-ol, and N-oxides, pharmaceutically acceptable salts, solvates, tautomers and stereochemical isomers thereof and the uses of such compounds as inhibitors of tubulin polymerization and for the treatment of solid tumors. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: January 29, 2008Publication date: September 18, 2008Inventors: Robert A. Galemmo, Dana L. Johnson, Umar S.M. Maharoof, Jay M. Mei, Robert W. Tuman
-
Patent number: 7208503Abstract: This invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; R1 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1NH—, C3-6cycloalkyl, hydroxymethyl or benzoyloxymethyl; R2 is hydrogen, C1-6alkyl, amino, aminocarbonyl, mono- or di(C1-6alkyl)amino, C1-6alkyloxycarbonyl, C1-6alkylcarbonylamino, hydroxy or C1-6alkyloxy; R3, R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1; is Ar2, Ar2CH2— or Het2; Ar1 and Ar2 optionally substituted phenyl; Het1 and Het2 are optionally substituted monocyclic heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.Type: GrantFiled: March 13, 2003Date of Patent: April 24, 2007Assignee: Janssen Pharmaceutica N.V.Inventors: Raymond Antoine Stokbroekx, Marc André Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Patent number: 7196110Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.Type: GrantFiled: May 14, 2003Date of Patent: March 27, 2007Assignee: Janssen Phamaceutica N.V.Inventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Jr., Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen
-
Patent number: 6833369Abstract: This invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; R1 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1NH—, C3-6cycloalkyl, hydroxymethyl or benzyloxymethyl; R2 is hydrogen, C1-6alkyl, amino, aminocarbonyl, mono- or di(C1-6alkyl)amino, C1-6alkyloxycarbonyl, C1-6alkylcarbonylamino, hydroxy or C1-6alkyloxy; R3, R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1; is Ar2, Ar2CH2— or Het2; Ar1 and Ar2 optionally substituted phenyl; Het1 and Het2 are optionally substituted monocyclic heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.Type: GrantFiled: October 19, 2001Date of Patent: December 21, 2004Assignee: Janssen Pharmaceutica, NVInventors: Raymond Antoine Stokbroekx, Marc André Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20040082639Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.Type: ApplicationFiled: May 14, 2003Publication date: April 29, 2004Inventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen
-
Publication number: 20040009987Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: October 19, 2001Publication date: January 15, 2004Inventors: Raymond Antoine Stokbroekx, Marc Andre Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20030181460Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: March 13, 2003Publication date: September 25, 2003Inventors: Raymond Antoine Stokbroekx, Marc Andre Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Patent number: 6602873Abstract: This invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein R1 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1—NH—, C3-6cycloalkyl, hydroxymethyl or benzyloxymethyl; R2 and R3 are hydrogen, or taken together may form a bivalent radical of formula —CH═CH—CH═CH—; R4, R5 and R6 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1; or when R4 and R5 are adjacent to each other they may be taken together to form a radical of formula —CH═CH—CH═CH—; A is a bivalent radical of formula NR7, NR7-Alk1-X-, NR7-Alk1-X-Alk2-, O-Alk1-X-, O-Alk1-X-Alk2- or S-Alk1-X-; wherein X is a direct bond, —O—, —S—, C═O, —NR8&mdType: GrantFiled: May 24, 2001Date of Patent: August 5, 2003Assignee: Janssen Pharamaceutica, N.V.Inventors: Raymond Antoine Stokbroekx, Marc André Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20020061890Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: November 19, 2001Publication date: May 23, 2002Inventors: Raymond Antoine Stokbroekx, Marc Andre Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman
-
Publication number: 20010046999Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: May 24, 2001Publication date: November 29, 2001Inventors: Raymond Antoine Stokbroekx, Marc Andre Ceusters, Marcel Jozef Maria Van der Aa, Marcel Gerebernus Maria Luyckx, Marc Willems, Robert W. Tuman